Abstract
Effective pharmacological and psychotherapeutic treatments are well established for obsessive-compulsive disorder (OCD). Serotonin reuptake inhibitors (SRIs) are first-line treatment and are of benefit to about half of patients. Augmentation of SRI treatment with low-dose neuroleptics is an evidence-based second-line strategy. Specialty psychotherapy is also used as both first-line and second-line treatment and can benefit many. However, a substantial number of patients do not respond to these treatments. New alternatives are urgently needed. This review summarizes evidence for these established pharmacotherapeutic strategies, and for others that have been investigated in refractory disease but are not supported by the same level of evidence. We focus on three neurotransmitter systems in the brain: serotonin, dopamine, and glutamate. We summarize evidence from genetic, neuroimaging, animal model, and other lines of investigation that probe these three systems in patients with OCD. We also review recent work on predictors of response to current treatments. While many studies suggest abnormalities that may provide insight into the pathophysiology of the disorder, most studies have been small, and non-replication of reported findings has been common. Nevertheless, the gradual accrual of evidence for neurotransmitter dysregulation may in time lead the way to new pharmacological strategies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aboujaoude E, Barry JJ, Gamel N (2009) Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29(1):51–55
Ackerman DL, Greenland S, Bystritsky A (1996a) Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy. Psychopharmacol Bull 32(1):157–165
Ackerman DL, Greenland S, Bystritsky A, Katz RJ (1996b) Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder. J Clin Psychopharmacol 16(4):324–328
Ackerman DL, Greenland S, Bystritsky A (1998) Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 18(3):185–192
Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, Bolwig TG, Knudsen GM (2005) Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 8(3):391–401
Adams TG, Bloch MH, Pittenger C (2017) Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder. J Clin Psychopharmacol 37(2):269–271
Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H (2012) N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 32(6):797–803
Afshar H, Akuchekian S, Mahaky B, Zarean E (2014) Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Res Med Sci 19(10):976–981
Ahmari SE (2016) Using mice to model obsessive compulsive disorder: from genes to circuits. Neuroscience 321:121–137
Ahmari SE, Dougherty DD (2015) Dissecting OCD circuits: from animal models to targeted treatments. Depress Anxiety 32(8):550–562
Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapoport JL (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51(10):794–803
Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322(5903):881–888
American Psychiatric Association. and American Psychiatric Association. DSM-5 Task Force (2013) Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, Washington
Andrade C (2019) Augmentation with memantine in obsessive-compulsive disorder. J Clin Psychiatry 80(6)
Anticevic A, Hu S, Zhang S, Savic A, Billingslea E, Wasylink S, Repovs G, Cole MW, Bednarski S, Krystal JH, Bloch MH, Li CS, Pittenger C (2014) Global resting-state functional magnetic resonance imaging analysis identifies frontal cortex, striatal, and cerebellar dysconnectivity in obsessive-compulsive disorder. Biol Psychiatry 75(8):595–605
Arrojo-Romero M, Tajes Alonso M, de Leon J (2013) Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry 2013:612459
Balachander S, Kodancha PG, Arumugham SS, Sekharan JT, Narayanaswamy JC, Reddy YCJ (2019) Effectiveness of venlafaxine in selective serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: experience from a specialty Clinic in India. J Clin Psychopharmacol 39(1):82–85
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, P. British Association for (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19(6):567–596
Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, Price LH (1994) Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51(4):309–317
Bastani B, Arora RC, Meltzer HY (1991) Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biol Psychiatry 30(2):131–139
Baumgarten HG, Grozdanovic Z (1998) Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry 35(Suppl):13–20
Bergin J, Verhulst B, Aggen SH, Neale MC, Kendler KS, Bienvenu OJ, Hettema JM (2014) Obsessive compulsive symptom dimensions and neuroticism: an examination of shared genetic and environmental risk. Am J Med Genet B Neuropsychiatr Genet 165B(8):647–653
Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E (2011) Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 72(5):716–721
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351–354
Berney A, Sookman D, Leyton M, Young SN, Benkelfat C (2006) Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry 59(9):853–857
Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK (2009) Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology 34(12):2489–2496
Biohaven Pharmaceuticals (2020). https://www.biohavenpharma.com/investors/news-events/press-releases/06-24-2020
BioSpace (2012) Transcept Pharmaceuticals, Inc.’s drug for obsessive compulsive Disroder fails trial. https://www.biospace.com/article/releases/transcept-pharmaceuticals-inc-s-drug-for-obsessive-compulsive-disorder-fails-trial−/. Accessed 22 May 2020
Bloch MH (2008) Emerging treatments for Tourette's disorder. Curr Psychiatry Rep 10(4):323–330
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11(7):622–632
Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF (2008a) Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 165(12):1532–1542
Bloch MH, Landeros-Weisenberger A, Sen S, Dombrowski P, Kelmendi B, Coric V, Pittenger C, Leckman JF (2008b) Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am J Med Genet B Neuropsychiatr Genet 147B(6):850–858
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C (2010) Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 15(8):850–855
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C (2012) Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry 72(11):964–970
Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, Leckman JF (2014) Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder. Mol Psychiatry 19(9):1025–1030
Boisseau CL, Schhwartzman CM, Rasmussen SA (2017) Quality of life and psychosocial functioning in OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Bortolato M, Pittenger C (2017) Modeling tics in rodents: conceptual challenges and paths forward. J Neurosci Methods 292:12–19
Boshuisen ML, den Boer JA (2000) Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology 152(1):74–79
Brandl EJ, Muller DJ, Richter MA (2012) Pharmacogenetics of obsessive-compulsive disorders. Pharmacogenomics 13(1):71–81
Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, Richter MA (2014) Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 14(2):176–181
Brennan BP, Rauch SL (2017) A review and synthesis of functional neuroimaging studies of obsessive-compulsive disorder. In: Pittenger C (ed) Obsessive-copulsive disorder: phenomenology, pathophysiology, and treatment. Oxford Univeristy Press, New York
Brennan BP, Rauch SL, Jensen JE, Pope HG Jr (2013) A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biol Psychiatry 73(1):24–31
Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR Jr (1998) FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 84(1):1–6
Bruno A, Mico U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR (2012) Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 26(11):1456–1462
Burkner PC, Bittner N, Holling H, Buhlmann U (2017) D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: a meta-analysis. PLoS One 12(3):e0173660
Cai J, Zhang W, Yi Z, Lu W, Wu Z, Chen J, Yu S, Fang Y, Zhang C (2013) Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology 230(1):49–55
Cappi C, Oliphant ME, Peter Z, Zai G, do Rosario MC, Sullivan CAW, Gupta AR, Hoffman EJ, Virdee M, Olfson E, Abdallah SB, Willsey AJ, Shavitt RG, Miguel EC, Kennedy JL, Richter MA, Fernandez TV (2019) De novo damaging DNA coding mutations are associated with obsessive-compulsive disorder and overlap with Tourette's disorder and autism. Biol Psychiatry
Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J (2019) Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry 176(11):931–938
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386–389
Castellan Baldan L, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, Anderson GM, Loring E, Gorczyca R, Billingslea E, Wasylink S, Panza KE, Ercan-Sencicek AG, Krusong K, Leventhal BL, Ohtsu H, Bloch MH, Hughes ZA, Krystal JH, Mayes L, de Araujo I, Ding YS, State MW, Pittenger C (2014) Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 81(1):77–90
Catapano F, Sperandeo R, Perris F, Lanzaro M, Maj M (2001) Insight and resistance in patients with obsessive-compulsive disorder. Psychopathology 34(2):62–68
Cavedini P, Erzegovesi S, Ronchi P, Bellodi L (1997) Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Eur Neuropsychopharmacol 7(1):45–49
Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30(9):1735–1740
Chiou YJ, Lin PY, Lee Y (2015) Risperidone as monotherapy for a patient with obsessive compulsive disorder comorbid with schizoaffective disorder: a case report. Clin Neuropharmacol 38(3):114–116
Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC (2004) Cognitive inflexibility after prefrontal serotonin depletion. Science 304(5672):878–880
Clarke H, Flint J, Attwood AS, Munafo MR (2010) Association of the 5- HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med 40(11):1767–1778
Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66(1):49–51
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58(5):424–428
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG (2017) Randomized, double-blind, placebo-controlled trial of N-Acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 78(7):e766–e773
D’Alcante CC, Diniz JB, Fossaluza V, Batistuzzo MC, Lopes AC, Shavitt RG, Deckersbach T, Malloy-Diniz L, Miguel EC, Hoexter MQ (2012) Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 39(2):310–317
da Conceicao Costa DL, Shavitt RG, Castro Cesar RC, Joaquim MA, Borcato S, Valerio C, Miguel EC, Diniz JB (2013) Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. J Psychiatr Res 47(11):1700–1707
Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, Neale BM, Yang J, Lee SH, Evans P, Barr CL, Bellodi L, Benarroch F, Berrio GB, Bienvenu OJ, Bloch MH, Blom RM, Bruun RD, Budman CL, Camarena B, Campbell D, Cappi C, Cardona Silgado JC, Cath DC, Cavallini MC, Chavira DA, Chouinard S, Conti DV, Cook EH, Coric V, Cullen BA, Deforce D, Delorme R, Dion Y, Edlund CK, Egberts K, Falkai P, Fernandez TV, Gallagher PJ, Garrido H, Geller D, Girard SL, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Haddad S, Heiman GA, Hemmings SM, Hounie AG, Illmann C, Jankovic J, Jenike MA, Kennedy JL, King RA, Kremeyer B, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner C, Lowe TL, Macciardi F, McCracken JT, McGrath LM, Mesa Restrepo SC, Moessner R, Morgan J, Muller H, Murphy DL, Naarden AL, Ochoa WC, Ophoff RA, Osiecki L, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Rauch SL, Renner TJ, Reus VI, Richter MA, Riddle MA, Robertson MM, Romero R, Rosario MC, Rosenberg D, Rouleau GA, Ruhrmann S, Ruiz-Linares A, Sampaio AS, Samuels J, Sandor P, Sheppard B, Singer HS, Smit JH, Stein DJ, Strengman E, Tischfield JA, Valencia Duarte AV, Vallada H, Van Nieuwerburgh F, Veenstra-Vanderweele J, Walitza S, Wang Y, Wendland JR, Westenberg HG, Shugart YY, Miguel EC, McMahon W, Wagner M, Nicolini H, Posthuma D, Hanna GL, Heutink P, Denys D, Arnold PD, Oostra BA, Nestadt G, Freimer NB, Pauls DL, Wray NR, Stewart SE, Mathews CA, Knowles JA, Cox NJ, Scharf JM (2013) Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet 9(10):e1003864
Delgado-Acevedo C, Estay SF, Radke AK, Sengupta A, Escobar AP, Henriquez-Belmar F, Reyes CA, Haro-Acuna V, Utreras E, Sotomayor-Zarate R, Cho A, Wendland JR, Kulkarni AB, Holmes A, Murphy DL, Chavez AE, Moya PR (2019) Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression. Neuropsychopharmacology 44(6):1163–1173
Delorme R, Chabane N, Callebert J, Falissard B, Mouren-Simeoni MC, Rouillon F, Launay JM, Leboyer M (2004) Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder. J Clin Psychopharmacol 24(1):18–23
Denys D, Burger H, van Megen H, de Geus F, Westenberg H (2003) A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 18(6):315–322
Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG (2004a) Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 55(10):1041–1045
Denys D, van Megen HJ, van der Wee N, Westenberg HG (2004b) A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65(1):37–43
Denys D, Zohar J, Westenberg HG (2004c) The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65(Suppl 14):11–17
Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG (2007) Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 68(5):747–753
Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN (2013) Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol 23(11):1423–1431
DeVeaugh-Geiss J, Landau P, Katz R (1989) Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 25(1):36–40
DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S (1990) Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull 26(1):54–59
Dietrich MO, Zimmer MR, Bober J, Horvath TL (2017) Hypothalamic Agrp neurons drive stereotypic behaviors beyond feeding. Cell 169(3):559
Dold M, Aigner M, Lanzenberger R, Kasper S (2015) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 18(9)
Ducasse D, Boyer L, Michel P, Loundou A, Macgregor A, Micoulaud-Franchi JA, Courtet P, Abbar M, Leboyer M, Fond G (2014) D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology 231(18):3765–3770
Eisen JL, Rasmussen SA, Phillips KA, Price LH, Davidson J, Lydiard RB, Ninan P, Piggott T (2001) Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry 42(6):494–497
El Mansari M, Blier P (2005) Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatry Neurosci 30(4):268–274
Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S (2016) Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci 70(8):332–341
Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L (2001) Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 21(5):488–492
Escobar AP, Wendland JR, Chavez AE, Moya PR (2019) The neuronal glutamate transporter EAAT3 in obsessive-compulsive disorder. Front Pharmacol 10:1362
Excellence, N. I. f. C (2006) Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. https://www.nice.org.uk/guidance/cg31. Accessed 15 Apr 2020
Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF (1998) Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 55(10):918–924
FDA (2012) FDA drug safety communications: revised recommendations for celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. Accessed 20 May 2020
Fernandez Cordoba E, Lopez-Ibor Alino J (1967) Use of monochlorimipramine in psychiatric patients who are resistant to other therapy. Actas Luso Esp Neurol Psiquiatr 26(2):119–147
Fernandez TV, Leckman JF, Pittenger C (2018) Genetic susceptibility in obsessive-compulsive disorder. Handb Clin Neurol 148:767–781
Ferrao YA, Shavitt RG, Bedin NR, de Mathis ME, Carlos Lopes A, Fontenelle LF, Torres AR, Miguel EC (2006) Clinical features associated to refractory obsessive-compulsive disorder. J Affect Disord 94(1–3):199–209
Feusner JD, Kerwin L, Saxena S, Bystritsky A (2009) Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 42(1):81–93
Fineberg NA, Gale T (2005) Evidence-based pharmacological treatments for obsessive-compulsive disorder. Int J Neuropsychopharmacol 8:107–129
Fineberg NA, Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, Stein DJ, Sareen J, Brown A, Sookman D, D. Accreditation Task Force of The Canadian Institute for Obsessive Compulsive (2015) Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res 227(1):114–125
Fontenelle L, Marques C, Engelhardt E, Versiani M (2001) Impaired set-shifting ability and therapeutic response in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 13(4):508–510
Friedman AA, Letai A, Fisher DE, Flaherty KT (2015) Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 15(12):747–756
Fullana MA, Zhu X, Alonso P, Cardoner N, Real E, Lopez-Sola C, Segalas C, Subira M, Galfalvy H, Menchon JM, Simpson HB, Marsh R, Soriano-Mas C (2017) Basolateral amygdala-ventromedial prefrontal cortex connectivity predicts cognitive behavioural therapy outcome in adults with obsessive-compulsive disorder. J Psychiatry Neurosci 42(6):378–385
Gadallah AHA, Ebada MA, Gadallah A, Ahmed H, Rashad W, Eid KA, Bahbah E, Alkanj S (2020) Efficacy and safety of N-acetylcysteine as add-on therapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis. J OCD Relat Disord 25:100529
Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S (2013) Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 47(2):175–180
Ghanizadeh A, Mohammadi MR, Bahraini S, Keshavarzi Z, Firoozabadi A, Alavi Shoshtari A (2017) Efficacy of N-Acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial. Iran J Psychiatry 12(2):134–141
Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS (1989a) Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 46(1):36–44
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989b) The Yale-Brown obsessive compulsive scale. II. Validity. Arch Gen Psychiatry 46(11):1012–1016
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989c) The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry 46(11):1006–1011
Graat I, Figee M, Denys D (2017) Neurotransmitter dysregulation in OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Grant PJ, Joseph LA, Farmer CA, Luckenbaugh DA, Lougee LC, Zarate CA Jr, Swedo SE (2014) 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology 39(6):1453–1459
Greenberg WM, Benedict MM, Doerfer J, Perrin M, Panek L, Cleveland WL, Javitt DC (2009) Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res 43(6):664–670
Grillault Laroche D, Gaillard A (2016) Induced obsessive compulsive symptoms (OCS) in schizophrenia patients under atypical 2 antipsychotics (AAPs): review and hypotheses. Psychiatry Res 246:119–128
Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J (2004) Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50(3):200–205
Group, C. C. S (1991) Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 48(8):730–738
Gruner P, Pittenger C (2017) Cognitive inflexibility in obsessive-compulsive disorder. Neuroscience 345:243–255
Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S (2013) In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology 228(4):633–640
Hamblin RJ, Park JM, Wu MS, Storch EA (2017) Variable insight in OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC, Leventhal BL, Cook EH Jr (2002) Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am J Med Genet 114(5):541–552
Harrison BJ, Soriano-Mas C, Pujol J, Ortiz H, Lopez-Sola M, Hernandez-Ribas R, Deus J, Alonso P, Yucel M, Pantelis C, Menchon JM, Cardoner N (2009) Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry 66(11):1189–1200
Harrison BJ, Pujol J, Cardoner N, Deus J, Alonso P, Lopez-Sola M, Contreras-Rodriguez O, Real E, Segalas C, Blanco-Hinojo L, Menchon JM, Soriano-Mas C (2013) Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder. Biol Psychiatry 73(4):321–328
Hasnain M, Vieweg WV (2014) QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 28(10):887–920
Hazari N, Narayanaswamy JC, Arumugham SS (2016) Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder. Expert Rev Neurother 16(10):1175–1191
Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR (2000) A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47(7):643–649
Hendler T, Goshen E, Tzila Zwas S, Sasson Y, Gal G, Zohar J (2003) Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Res 124(2):87–103
Hesse S, Muller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K (2005) Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res 140(1):63–72
Hezel DM, Beattie K, Stewart SE (2009) Memantine as an augmenting agent for severe pediatric OCD. Am J Psychiatry 166(2):237
Ho Pian KL, van Megen HJ, Ramsey NF, Mandl R, van Rijk PP, Wynne HJ, Westenberg HG (2005) Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res 138(2):89–97
Hoexter MQ, Dougherty DD, Shavitt RG, D'Alcante CC, Duran FL, Lopes AC, Diniz JB, Batistuzzo MC, Evans KC, Bressan RA, Busatto GF, Miguel EC (2013) Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder. Eur Neuropsychopharmacol 23(7):569–580
Hoexter MQ, Diniz JB, Lopes AC, Batistuzzo MC, Shavitt RG, Dougherty DD, Duran FL, Bressan RA, Busatto GF, Miguel EC, Sato JR (2015) Orbitofrontal thickness as a measure for treatment response prediction in obsessive-compulsive disorder. Depress Anxiety 32(12):900–908
Hollander E, Doernberg E, Shavitt R, Waterman RJ, Soreni N, Veltman DJ, Sahakian BJ, Fineberg NA (2016) The cost and impact of compulsivity: a research perspective. Eur Neuropsychopharmacol 26(5):800–809
Hood SD, Broyd A, Robinson H, Lee J, Hudaib AR, Hince DA (2017) Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder. J Psychopharmacol 31(12):1615–1623
Hsieh HJ, Lue KH, Tsai HC, Lee CC, Chen SY, Kao PF (2014) L-3,4-Dihydroxy-6-[F-18]fluorophenylalanine positron emission tomography demonstrating dopaminergic system abnormality in the brains of obsessive-compulsive disorder patients. Psychiatry Clin Neurosci 68(4):292–298
Humble M, Bejerot S, Bergqvist PB, Bengtsson F (2001) Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. Biol Psychiatry 49(4):360–368
Hussain MZ, Ahad A (1970) Treatment of obsessive-compulsive neurosis. Can Med Assoc J 103(6):648
Hussain A, Dar MA, Wani RA, Shah MS, Jan MM, Malik YA, Chandel RK, Margoob MA (2015) Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia. Indian J Psychol Med 37(2):154–158
Hutton LMJ, Cave AJ, St-Jean R, Banh HL (2017) Should we be worried about QTc prolongation using citalopram? A review. J Pharm Pract 30(3):353–358
Hybel KA, Mortensen EL, Lambek R, Hojgaard D, Thomsen PH (2017) Executive function predicts cognitive-behavioral therapy response in childhood obsessive-compulsive disorder. Behav Res Ther 99:11–18
Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M (1983) Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 40(6):605–612
Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL (1985) Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 20(11):1174–1188
International Obsessive Compulsive Disorder Foundation Genetics Consortium (IOCDF-GC), C. and OCD Collaborative Genetic Association (OCGAS) (2018) Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. Mol Psychiatry 23(5):1181–1188
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH (2016) Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J Clin Psychiatry 77(5):e605–e611
Iyo M, Sekine Y, Matsunaga T, Tsukamoto T, Takei N, Mori N (1999) Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report. J Clin Psychiatry 60(5):337–338
Jhanda S, Singla N, Grover S (2016) Methylphenidate-induced obsessive-compulsive symptoms: a case report and review of literature. J Pediatr Neurosci 11(4):316–318
Johnson MW, Hendricks PS, Barrett FS, Griffiths RR (2019) Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther 197:83–102
Kaplan GB, Moore KA (2011) The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav 99(2):217–228
Karameh WK, Khani M (2015) Intravenous clomipramine for treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol 19(2)
Karthik S, Sharma LP, Narayanaswamy JC (2020) Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat 16:1003–1013
Katz RJ, DeVeaugh-Geiss J, Landau P (1990) Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 28(5):401–414
Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21(3):169–184
Khalkhali M, Aram S, Zarrabi H, Kafie M, Heidarzadeh A (2016) Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry 11(2):104–114
Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS (2003) Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging 30(12):1637–1643
Kim M, Kwak S, Yoon YB, Kwak YB, Kim T, Cho KIK, Lee TY, Kwon JS (2019) Functional connectivity of the raphe nucleus as a predictor of the response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Neuropsychopharmacology 44(12):2073–2081
Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP (2002) R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27(6):949–959
Koran LM, Pallanti S, Quercioli L (2001) Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 11(2):169–172
Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN (2005) Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 66(4):515–520
Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, A. American Psychiatric (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164(7 Suppl):5–53
Koran LM, Aboujaoude E, Gamel NN (2009) Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 70(11):1530–1535
Korff S, Stein DJ, Harvey BH (2008) Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 32(2):348–355
Kouris S (1998) Methylphenidate-induced obsessive-compulsiveness. J Am Acad Child Adolesc Psychiatry 37(2):135
Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX (2017) Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology 234(13):2031–2046
Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS (2019) Ketamine: a paradigm shift for depression research and treatment. Neuron 101(5):774–778
Kulz AK, Meinzer S, Kopasz M, Voderholzer U (2007) Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results. Neuropsychobiology 56(2–3):127–131
Kumar TC, Khanna S (2000) Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 34(3):527–528
Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V (2006) N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 184(2):254–256
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V (2010) Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord 121(1–2):175–179
Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL et al (1995) Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12(1):73–86
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292):1527–1531
Lochner C et al (2001) Venlafaxine in obsessive compulsive disorder. In: Fifth Internatonal obsessive compulsive disorder conference, Sardinia, Italy
Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A (2003) Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuro-Psychopharmacol Biol Psychiatry 27(3):333–346
Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB (1992) Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res 42(1):41–51
Marazziti D, Rossi A, Gemignani A, Giannaccini G, Pfanner C, Milanfranchi A, Presta S, Lucacchini A, Cassano GB (1996) Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients. Neuropsychobiology 34(4):184–187
Marazziti D, Pfanner C, Palego L, Gemignani A, Milanfranchi A, Ravagli S, Lensi P, Presta S, Cassano GB (1997) Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine. Pharmacopsychiatry 30(6):245–249
Marazziti D, Dell'Osso L, Presta S, Pfanner C, Rossi A, Masala I, Baroni S, Giannaccini G, Lucacchini A, Cassano GB (1999) Platelet [3H]paroxetine binding in patients with OCD-related disorders. Psychiatry Res 89(3):223–228
Marinova Z, Chuang DM, Fineberg N (2017) Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol 15(7):977–995
Markianos M, Lafazanos S, Koutsis G, Sfagos C, Seretis A (2009) CSF neurotransmitter metabolites and neuropsychiatric symptomatology in patients with normal pressure hydrocephalus. Clin Neurol Neurosurg 111(3):231–234
Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980) Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 136:1–25
Marroni SS, Nakano FN, Gati CD, Oliveira JA, Antunes-Rodrigues J, Garcia-Cairasco N (2007) Neuroanatomical and cellular substrates of hypergrooming induced by microinjection of oxytocin in central nucleus of amygdala, an experimental model of compulsive behavior. Mol Psychiatry 12(12):1103–1117
Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L (2002) Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychother Psychosom 71(5):255–262
Mataix-Cols D, Fernandez de la Cruz L, Monzani B, Rosenfield D, Andersson E, Perez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks GJ, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Strohle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, Ruck C, D. C. S. A. C. the, Altemus M, Anderson P, Cukor J, Finck C, Geffken GR, Golfels F, Goodman WK, Gutner C, Heyman I, Jovanovic T, Lewin AB, McNamara JP, Murphy TK, Norrholm S, Thuras P (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiat 74(5):501–510
Mattheisen M, Samuels JF, Wang Y, Greenberg BD, Fyer AJ, McCracken JT, Geller DA, Murphy DL, Knowles JA, Grados MA, Riddle MA, Rasmussen SA, McLaughlin NC, Nurmi EL, Askland KD, Qin HD, Cullen BA, Piacentini J, Pauls DL, Bienvenu OJ, Stewart SE, Liang KY, Goes FS, Maher B, Pulver AE, Shugart YY, Valle D, Lange C, Nestadt G (2015) Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry 20(3):337–344
McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH (1993) The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 13(5):354–358
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51(4):302–308
McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH (1995) Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152(12):1812–1814
McDougle CJ, Barr LC, Goodman WK, Price LH (1999) Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24(1):1–24
McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57(8):794–801
Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L (2018) Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry 51(6):263–269
Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR (2019) A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res 282:112602
Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 3(2):143–152
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735–1740
Mowla A, Boostani S, Dastgheib SA (2016) Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-blind controlled clinical trial. J Clin Psychopharmacol 36(6):720–723
Naguy A, Alamiri B, Al-Khadhari S, Francis K (2016) Lamotrigine augmentation in treatment-resistant pediatric obsessive-compulsive disorder with a 16 month follow-up. J Child Adolesc Psychopharmacol 26(8):769–772
NHS (2011) Citalopram and escitalopram: QT interval prolongation. Drug Saf Update 5(5):A1
Nikolaus S, Muller HW, Hautzel H (2016) Different patterns of 5-HT receptor and transporter dysfunction in neuropsychiatric disorders--a comparative analysis of in vivo imaging findings. Rev Neurosci 27(1):27–59
NIMH (2020). https://www.nimh.nih.gov/about/strategic-planning-reports/goal-3-strive-for-prevention-and-cures.shtml. Accessed 1 July 2020
Olatunji BO, Ebesutani C, Abramowitz JS (2017) Examination of a Bifactor model of obsessive-compulsive symptom dimensions. Assessment 24(1):45–59
Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott A, Norman TR (2009) Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. J Affect Disord 114(1–3):321–326
Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott AM, Norman TR (2010) Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder. Psychiatry Res 183(1):85–88
O'Neill J, Piacentini J, Chang S, Ly R, Lai TM, Armstrong CC, Bergman L, Rozenman M, Peris T, Vreeland A, Mudgway R, Levitt JG, Salamon N, Posse S, Hellemann GS, Alger JR, McCracken JT, Nurmi EL (2017) Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: randomized clinical trial. Neuropsychopharmacology 42(12):2414–2422
O'Regan JB (1970) Treatment of obsessive--compulsive neurosis with haloperidol. Can Med Assoc J 103(2):167–168
Pallanti S, Quercioli L, Koran LM (2002) Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 63(9):796–801
Pallanti S, Quercioli L, Bruscoli M (2004) Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 65(10):1394–1399
Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S (2016) N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 41(2):214–219
Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F (2008) In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage 42(1):306–314
Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R (1987) Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 144(12):1543–1548
Phillips KA, Albertini RS, Rasmussen SA (2002) A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 59(4):381–388
Pian KL, Westenberg HG, van Megen HJ, den Boer JA (1998) Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology 140(3):365–370
Piantadosi SC, Chamberlain BL, Glausier JR, Lewis DA, Ahmari SE (2019) Lower excitatory synaptic gene expression in orbitofrontal cortex and striatum in an initial study of subjects with obsessive compulsive disorder. Mol Psychiatry
Pittenger C (2014) Animal models of Tourette syndrome and obsessive-compulsive disorder. In: LeDoux M (ed) Animal models of movement disorders. Elsevier, Academic Press, San Deigo, pp 748–766
Pittenger C (2015) Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann 45(6):308–315
Pittenger C (2017a) Histidine decarboxylase knockout mice as a model of the pathophysiology of Tourette syndrome and related conditions. Handb Exp Pharmacol 241:189–215
Pittenger C (2017b) The neurobiology of tic disorders and obsessive-compulsive disorder: human and animal studies. In: Nestler EJ, Buxbaum JD, Sklar P, Charney DS (eds) Nestler and Charney’s neurobiology of mental illness. Oxford University Press, New York, pp 879–890
Pittenger C (2017c) The pharmacological treatment of refractory OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Pittenger C, Krystal JH, Coric V (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3(1):69–81
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G (2008a) Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22(9):761–786
Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V (2008b) Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol 28(3):363–367
Pittenger C, Bloch MH, Williams K (2011) Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 132(3):314–332
Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V (2015) Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry 76(8):1075–1084
Pittenger C, Adams TG Jr, Gallezot JD, Crowley MJ, Nabulsi N, James R, Gao H, Kichuk SA, Simpson R, Billingslea E, Hannestad J, Bloch M, Mayes L, Bhagwagar Z, Carson RE (2016) OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. J Affect Disord 196:87–96
Pittenger C, Dulawa S, Thompson SL (2017a) Animal models of OCD: a conceptual framework. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Pittenger C, Gruner P, Adams TA, Kelmendi B (2017b) The dynamics of obsessive-compulsive disorder: a heuristic framework. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Pogarell O, Hamann C, Popperl G, Juckel G, Chouker M, Zaudig M, Riedel M, Moller HJ, Hegerl U, Tatsch K (2003) Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 54(12):1406–1413
Poyurovsky M (2017) Obsessive-compulsive symptoms in schizophrenia. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stampfli P, Liechti ME, Seifritz E, Vollenweider FX (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27(3):451–457
Qin H, Samuels JF, Wang Y, Zhu Y, Grados MA, Riddle MA, Greenberg BD, Knowles JA, Fyer AJ, McCracken JT, Murphy DL, Rasmussen SA, Cullen BA, Piacentini J, Geller D, Stewart SE, Pauls D, Bienvenu OJ, Goes FS, Maher B, Pulver AE, Valle D, Lange C, Mattheisen M, McLaughlin NC, Liang KY, Nurmi EL, Askland KD, Nestadt G, Shugart YY (2016) Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry 21(2):270–276
Rasmussen SA, Eisen JL (1990) Epidemiology of obsessive compulsive disorder. J Clin Psychiatry 51(Suppl):10–13; discussion 14
Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O'Connor K (1997) A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12(6):309–316
Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA (2002) Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27(5):782–791
Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995) Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 56(8):368–373
Reggente N, Moody TD, Morfini F, Sheen C, Rissman J, O'Neill J, Feusner JD (2018) Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive-compulsive disorder. Proc Natl Acad Sci U S A 115(9):2222–2227
Reid JE, Reghunandanan S, Roberts A, Fineberg NA (2017) Standard evidence-based pharmacological treatment for OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM, B. and the Work Group on and a. D. o. t. A. P. A. C. o. R. Novel Treatments (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 177(5):391–410
Richardson R, Ledgerwood L, Cranney J (2004) Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem 11(5):510–516
Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR (2009) Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301(23):2462–2471
Rivers-Bulkeley N, Hollender MH (1982) Successful treatment of obsessive-compulsive disorder with loxapine. Am J Psychiatry 139(10):1345–1346
Rodriguez CI, Kegeles LS, Flood P, Simpson HB (2011) Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 72(4):567–569
Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38(12):2475–2483
Rodriguez CI, Levinson A, Zwerling J, Vermes D, Simpson HB (2016a) Open-label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J Clin Psychiatry 77(5):688–689
Rodriguez CI, Wheaton M, Zwerling J, Steinman SA, Sonnenfeld D, Galfalvy H, Simpson HB (2016b) Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. J Clin Psychiatry 77(3):408–409
Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39(9):1096–1103
Rosenberg DR, MacMillan SN, Moore GJ (2001) Brain anatomy and chemistry may predict treatment response in paediatric obsessive--compulsive disorder. Int J Neuropsychopharmacol 4(2):179–190
Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ (2004) Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43(9):1146–1153
Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010) The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15(1):53–63
Sahraian A, Bigdeli M, Ghanizadeh A, Akhondzadeh S (2014) Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial. J Affect Disord 166:201–205
Sahraian A, Jahromi LR, Ghanizadeh A, Mowla A (2017) Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 37(2):246–249
Sallee FR, Richman H, Beach K, Sethuraman G, Nesbitt L (1996) Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 35(12):1647–1656
Sampaio AS, Hounie AG, Petribu K, Cappi C, Morais I, Vallada H, do Rosario MC, Stewart SE, Fargeness J, Mathews C, Arnold P, Hanna GL, Richter M, Kennedy J, Fontenelle L, de Braganca Pereira CA, Pauls DL, Miguel EC (2015) COMT and MAO-A polymorphisms and obsessive-compulsive disorder: a family-based association study. PLoS One 10(3):e0119592
Sanematsu H, Nakao T, Yoshiura T, Nabeyama M, Togao O, Tomita M, Masuda Y, Nakatani E, Nakagawa A, Kanba S (2010) Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. J Psychiatr Res 44(4):193–200
Sari Y (2004) Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev 28(6):565–582
Sassano-Higgins SA, Pato MT (2015) Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: a meta-analysis. J Pharmacol Pharmacother 6(1):36–38
Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter LR Jr (1999) Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21(6):683–693
Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr (2003) Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 160(3):522–532
Scheinost D, Stoica T, Wasylink S, Gruner P, Saksa J, Pittenger C, Hampson M (2014) Resting state functional connectivity predicts neurofeedback response. Front Behav Neurosci 8:338
Schirmbeck F, Zink M (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10(1):88–95
Schirmbeck F, Zink M (2013) Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol 4:99
Schirmbeck F, Nieratschker V, Frank J, Englisch S, Rausch F, Meyer-Lindenberg A, Rietschel M, Zink M (2012) Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents. Psychiatr Genet 22(5):245–252
Schneier FR, Martinez D, Abi-Dargham A, Zea-Ponce Y, Simpson HB, Liebowitz MR, Laruelle M (2008) Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 25(1):1–7
Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Callovini G, Piacentino D, Gasperoni C, Brugnoli R, Ferri VR, Girardi N, Tatarelli R, Ferracuti S, Angeletti G, Girardi P, Del Casale A (2015) Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol 30(2):70–84
Serby M (2003) Methylphenidate-induced obsessive-compulsive symptoms in an elderly man. CNS Spectr 8(8):612–613
Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer MA, Hen R, Dulawa SC (2009) Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry 65(5):401–408
Sharma LP, Thamby A, Balachander S, Janardhanan CN, Jaisoorya TS, Arumugham SS, Reddy YCJ (2020) Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. Asian J Psychiatr 52:102183
Shin DJ, Jung WH, He Y, Wang J, Shim G, Byun MS, Jang JH, Kim SN, Lee TY, Park HY, Kwon JS (2014) The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol Psychiatry 75(8):606–614
Shmelkov SV, Hormigo A, Jing D, Proenca CC, Bath KG, Milde T, Shmelkov E, Kushner JS, Baljevic M, Dincheva I, Murphy AJ, Valenzuela DM, Gale NW, Yancopoulos GD, Ninan I, Lee FS, Rafii S (2010) Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 16(5):598–602, 591p following 602
Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang DR, Abi-Dargham A, Liebowitz MR, Laruelle M (2003) Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry 54(12):1414–1421
Simpson HB, Slifstein M, Bender J Jr, Xu X, Hackett E, Maher MJ, Abi-Dargham A (2011) Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907. Biol Psychiatry 70(9):897–904
Simpson HB, Shungu DC, Bender J Jr, Mao X, Xu X, Slifstein M, Kegeles LS (2012) Investigation of cortical glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology 37(12):2684–2692
Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R (2013) Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiat 70(11):1190–1199
Sinopoli VM, Burton CL, Kronenberg S, Arnold PD (2017) A review of the role of serotonin system genes in obsessive-compulsive disorder. Neurosci Biobehav Rev 80:372–381
Skapinakis P, Papatheodorou T, Mavreas V (2007) Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17(2):79–93
Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, Lewis G (2016) Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 3(8):730–739
Smeraldi E, Diaferia G, Erzegovesi S, Lucca A, Bellodi L, Moja EA (1996) Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 40(5):398–402
Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008) Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 1:CD001765
Stein DJ, Andersen EW, Overo KF (2007) Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Braz J Psychiatry 29(4):303–307
Stern ER, Shahab R, Grimaldi SJ, Leibu E, Murrough JW, Fleysher L, Parides MK, Coffey BJ, Burdick KE, Goodman WK (2019) High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology 44(2):390–398
Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA (2010) A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 30(1):34–39
Stewart SE, Mayerfeld C, Arnold PD, Crane JR, O'Dushlaine C, Fagerness JA, Yu D, Scharf JM, Chan E, Kassam F, Moya PR, Wendland JR, Delorme R, Richter MA, Kennedy JL, Veenstra-VanderWeele J, Samuels J, Greenberg BD, McCracken JT, Knowles JA, Fyer AJ, Rauch SL, Riddle MA, Grados MA, Bienvenu OJ, Cullen B, Wang Y, Shugart YY, Piacentini J, Rasmussen S, Nestadt G, Murphy DL, Jenike MA, Cook EH, Pauls DL, Hanna GL, Mathews CA (2013a) Meta-analysis of association between obsessive-compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1. Am J Med Genet B Neuropsychiatr Genet 162B(4):367–379
Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews CA, Arnold PD, Evans PD, Gamazon ER, Davis LK, Osiecki L, McGrath L, Haddad S, Crane J, Hezel D, Illman C, Mayerfeld C, Konkashbaev A, Liu C, Pluzhnikov A, Tikhomirov A, Edlund CK, Rauch SL, Moessner R, Falkai P, Maier W, Ruhrmann S, Grabe HJ, Lennertz L, Wagner M, Bellodi L, Cavallini MC, Richter MA, Cook EH Jr, Kennedy JL, Rosenberg D, Stein DJ, Hemmings SM, Lochner C, Azzam A, Chavira DA, Fournier E, Garrido H, Sheppard B, Umana P, Murphy DL, Wendland JR, Veenstra-VanderWeele J, Denys D, Blom R, Deforce D, Van Nieuwerburgh F, Westenberg HG, Walitza S, Egberts K, Renner T, Miguel EC, Cappi C, Hounie AG, do Rosario MC, Sampaio AS, Vallada H, Nicolini H, Lanzagorta N, Camarena B, Delorme R, Leboyer M, Pato CN, Pato MT, Voyiaziakis E, Heutink P, Cath DC, Posthuma D, Smit JH, Samuels J, Bienvenu OJ, Cullen B, Fyer AJ, Grados MA, Greenberg BD, McCracken JT, Riddle MA, Wang Y, Coric V, Leckman JF, Bloch M, Pittenger C, Eapen V, Black DW, Ophoff RA, Strengman E, Cusi D, Turiel M, Frau F, Macciardi F, Gibbs JR, Cookson MR, Singleton A, C. North American Brain Expression, Hardy J, U. K. B. E. Database, Crenshaw AT, Parkin MA, Mirel DB, Conti DV, Purcell S, Nestadt G, Hanna GL, Jenike MA, Knowles JA, Cox N, Pauls DL (2013b) Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry 18(7):788–798
Storch EA, Larson MJ, Shapira NA, Ward HE, Murphy TK, Geffken GR, Valerio H, Goodman WK (2006) Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety 23(7):429–433
Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland R, Rapoport SI, Rapoport JL (1989) Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry 46(6):518–523
Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL (1992) Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry 49(9):690–694
Szechtman H, Sulis W, Eilam D (1998) Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112(6):1475–1485
Szechtman H, Ahmari SE, Beninger RJ, Eilam D, Harvey BH, Edemann-Callesen H, Winter C (2017) Obsessive-compulsive disorder: Insights from animal models. Neurosci Biobehav Rev 76(Pt B):254–279
Szechtman H, Harvey BH, Woody EZ, Hoffman KL (2020) The psychopharmacology of obsessive-compulsive disorder: a preclinical roadmap. Pharmacol Rev 72(1):80–151
Talati A, Odgerel Z, Wickramaratne PJ, Norcini-Pala A, Skipper JL, Gingrich JA, Weissman MM (2017) Associations between serotonin transporter and behavioral traits and diagnoses related to anxiety. Psychiatry Res 253:211–219
Taylor S (2013) Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. Mol Psychiatry 18(7):799–805
Taylor S (2016) Disorder-specific genetic factors in obsessive-compulsive disorder: a comprehensive meta-analysis. Am J Med Genet B Neuropsychiatr Genet 171B(3):325–332
Ting JT, Feng G (2008) Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genom 2:62–75
Torres AR, Fontenelle LH, Shhavitt RG, Hoexter MQ, Pittenger C, Miguel EC (2017) Epidemiology, comorbidity, and burden of OCD. In: Pittenger C (ed) Obsessive-compulsive disorder: phenomenology, pathophysiology, and treatment. Oxford University Press, New York
Trethowan WH, Scott PA (1955) Chlorpromazine in obsessive-compulsive and allied disorders. Lancet 268(6868):781–785
Uzun O (2010) Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacol 24(3):425–427
van der Straten AL, Denys D, van Wingen GA (2017) Impact of treatment on resting cerebral blood flow and metabolism in obsessive compulsive disorder: a meta-analysis. Sci Rep 7(1):17464
van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, Kahn RS, Westenberg HM (2004) Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry 161(12):2201–2206
Vandebroek I, Odberg FO (1997) Effect of apomorphine on the conflict-induced jumping stereotypy in bank voles. Pharmacol Biochem Behav 57(4):863–868
Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J (2014) Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry 14:317
Vulink NC, Denys D, Westenberg HG (2005) Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry 66(2):228–230
Weizman A, Mandel A, Barber Y, Weitz R, Cohen A, Mester R, Rehavi M (1992) Decreased platelet imipramine binding in Tourette syndrome children with obsessive-compulsive disorder. Biol Psychiatry 31(7):705–711
Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding JD, Feliciano C, Chen M, Adams JP, Luo J, Dudek SM, Weinberg RJ, Calakos N, Wetsel WC, Feng G (2007) Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448(7156):894–900
Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG, Ren-Patterson RF, Murphy DL (2009) A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry 66(4):408–416
Williams K, Bloch MH, State MW, Pittenger C (2013) In: Buxbaum JD, Sklar P, Nestler EJ et al (eds) Tourette syndrome. Neurobiology of mental illness, 4th edn. Oxford University Press, New York
Willour VL, Yao Shugart Y, Samuels J, Grados M, Cullen B, Bienvenu OJ 3rd, Wang Y, Liang KY, Valle D, Hoehn-Saric R, Riddle M, Nestadt G (2004) Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am J Hum Genet 75(3):508–513
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46(D1):D1074–D1082
Woehrle NS, Klenotich SJ, Jamnia N, Ho EV, Dulawa SC (2013) Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation. Psychopharmacology 227(3):545–551
Woolley JB, Heyman I (2003) Dexamphetamine for obsessive-compulsive disorder. Am J Psychiatry 160(1):183
Wu PL, Tang HS, Lane HY, Tsai CA, Tsai GE (2011) Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J Clin Psychopharmacol 31(3):369–374
Yazici KU, Percinel I (2015) N-Acetylcysteine augmentation in children and adolescents diagnosed with treatment-resistant obsessive-compulsive disorder: case series. J Clin Psychopharmacol 35(4):486–489
Yin D, Zhang C, Lv Q, Chen X, Zeljic K, Gong H, Zhan S, Jin H, Wang Z, Sun B (2018) Dissociable frontostriatal connectivity: mechanism and predictor of the clinical efficacy of capsulotomy in obsessive-compulsive disorder. Biol Psychiatry 84(12):926–936
Yoshimura R, Kaneko S, Shinkai K, Nakamura J (2006) Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci 60(3):389–393
Yun JY, Jang JH, Kim SN, Jung WH, Kwon JS (2015) Neural correlates of response to pharmacotherapy in obsessive-compulsive disorder: individualized cortical morphology-based structural covariance. Prog Neuro-Psychopharmacol Biol Psychiatry 63:126–133
Zai G, Brandl EJ, Muller DJ, Richter MA, Kennedy JL (2014) Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics 15(8):1147–1157
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856–864
Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H (2019) Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: a randomized double-blind, placebo-controlled study. Eur Neuropsychopharmacol 29(3):397–404
Zike ID, Chohan MO, Kopelman JM, Krasnow EN, Flicker D, Nautiyal KM, Bubser M, Kellendonk C, Jones CK, Stanwood G, Tanaka KF, Moore H, Ahmari SE, Veenstra-VanderWeele J (2017) OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proc Natl Acad Sci U S A 114(22):5719–5724
Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC (2013) Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 170(6):642–650
Zohar J, Kennedy JL, Hollander E, Koran LM (2004) Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J Clin Psychiatry 65(Suppl 14):18–21
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pittenger, C. (2021). Pharmacotherapeutic Strategies and New Targets in OCD. In: Fineberg, N.A., Robbins, T.W. (eds) The Neurobiology and Treatment of OCD: Accelerating Progress. Current Topics in Behavioral Neurosciences, vol 49. Springer, Cham. https://doi.org/10.1007/7854_2020_204
Download citation
DOI: https://doi.org/10.1007/7854_2020_204
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-75392-4
Online ISBN: 978-3-030-75393-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)